Yidu Tech reported a return to profitability for the year ended 31 March 2026, posting net earnings of RMB78.77 million versus a RMB135.22 million loss a year earlier. Revenue rose 14.6% to RMB819.30 million, while gross profit expanded 24.8% to RMB298.50 million, lifting gross margin 2.9 percentage points to 36.4%.
Segment performance • AI for Medical (Big Data Platform and Solutions) generated RMB381.03 million, up 10.2%, with gross margin improving to 39.7% from 29.7%. • AI for Life Sciences (Life Sciences Solutions) contributed RMB270.42 million, a 9.4% rise; segment margin eased to 31.9% from 33.5%. • AI for Care (Health Management Platform and Solutions) surged 37.6% to RMB167.85 million; margin narrowed to 36.4% from 44.1% on product-mix changes.
Cost discipline underpinned earnings recovery. Selling and marketing spend fell 5.5% to RMB131.58 million, administrative expenses dropped 54.7% to RMB66.32 million, and R&D outlays declined 11.6% to RMB164.89 million. Operating profit reached RMB87.83 million, reversing a RMB134.15 million loss in FY25.
Cash flow and balance sheet Net cash used in operating activities contracted 91.2% to RMB21.99 million, turning positive (RMB29.30 million inflow) in 2H. Total cash, term deposits and restricted balances stood at RMB2.08 billion at end-March, down from RMB3.31 billion a year earlier. Total equity was RMB3.70 billion; total liabilities declined to RMB612.04 million.
Dividend and capital actions The board proposed a first-time final dividend of HK$0.04 per share, subject to shareholder approval at the 28 August 2026 AGM, payable on or about 16 September 2026. During FY26 the company repurchased 50.02 million shares for HK$283.53 million, which are held as treasury stock.
Operational highlights • YiduCore processed about 9 billion authorised medical records covering 1.32 billion patient visits and now spans 100+ disease categories. • AI for Medical solutions served 133 top hospitals and 54 regulators, while the Clinical Assistant Copilot 2.0 and Yidu Smart Evidence were rolled out. • AI for Life Sciences supported 98 clients—including 17 of the top 20 multinational pharma firms—and participated in 516 clinical studies. • AI for Care maintained leadership in major city “Hui Min Bao” schemes, with Shenzhen enrolment above 6 million for three consecutive years and Beijing cumulative insured topping 19 million; active health-platform users exceeded 22 million.
Strategic outlook Management will focus on enhancing the YiduCore platform, expanding disease-centric solutions in oncology, diabetes and other key areas, scaling intelligent-agent deployments across clinical and administrative workflows, and pursuing selective international expansion. Prudent capital allocation will prioritise R&D, scenario penetration and potential M&A, while sustaining financial discipline.